FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2024930671> ?p ?o ?g. }

• W2024930671 endingPage "2324" @default.
• W2024930671 startingPage "2316" @default.
• W2024930671 abstract "ObjectiveThe aim of the present study was to construct a new drug delivery system for milrinone using microparticles. This novel technology enhances drug bioavailability and decreases toxicity, with future implications for the treatment of end-stage heart failure.MethodsPolylactic-co-glycolic acid microparticles (PLGA-MPs) loaded with milrinone were prepared using a double emulsion-solvent evaporation technique. In vitro release kinetics was evaluated at physiologic conditions. A total of 24 female Lewis rats underwent left coronary artery ligation. One week after ligation, all rats were randomized to 1 of 3 groups (n = 8 per group). Group I received an intravenous injection of PLGA-MPs alone; group II, a bolus intravenous injection of milrinone; and group III an intravenous injection of milrinone-PLGA-MPs. All injections were administrated slowly by way of the tail vein over 10 minutes. Transthoracic echocardiography, noninvasive heart rate monitoring, and blood pressure measurements were performed at different predetermined intervals before and for 24 hours after the injection. All rats survived for 24 hours and were then killed by euthanasia. Serum plasma was taken for cytokine assays and determination of milrinone levels using high-performance liquid chromatography.ResultsGroup III had a significantly greater left ventricular ejection fraction at 90 minutes and 3, 6, and 12 hours after treatment compared with the other groups. The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1.7 ± 2.4 ng/mL; group III, 9.1 ± 2.2 ng/mL; P < .05). The intercellular adhesion molecule and cytokine-induced neutrophil chemoattractant-1 levels were significantly lower in group III than in the other 2 groups (P < .05).ConclusionsDrug encapsulation using microparticles can prolong the effects of milrinone. We propose a new strategy for future drug delivery in patients with end-stage heart failure. The aim of the present study was to construct a new drug delivery system for milrinone using microparticles. This novel technology enhances drug bioavailability and decreases toxicity, with future implications for the treatment of end-stage heart failure. Polylactic-co-glycolic acid microparticles (PLGA-MPs) loaded with milrinone were prepared using a double emulsion-solvent evaporation technique. In vitro release kinetics was evaluated at physiologic conditions. A total of 24 female Lewis rats underwent left coronary artery ligation. One week after ligation, all rats were randomized to 1 of 3 groups (n = 8 per group). Group I received an intravenous injection of PLGA-MPs alone; group II, a bolus intravenous injection of milrinone; and group III an intravenous injection of milrinone-PLGA-MPs. All injections were administrated slowly by way of the tail vein over 10 minutes. Transthoracic echocardiography, noninvasive heart rate monitoring, and blood pressure measurements were performed at different predetermined intervals before and for 24 hours after the injection. All rats survived for 24 hours and were then killed by euthanasia. Serum plasma was taken for cytokine assays and determination of milrinone levels using high-performance liquid chromatography. Group III had a significantly greater left ventricular ejection fraction at 90 minutes and 3, 6, and 12 hours after treatment compared with the other groups. The milrinone plasma level was significantly greater in group III than in the other groups (group I, 0 ng/mL; group II, 1.7 ± 2.4 ng/mL; group III, 9.1 ± 2.2 ng/mL; P < .05). The intercellular adhesion molecule and cytokine-induced neutrophil chemoattractant-1 levels were significantly lower in group III than in the other 2 groups (P < .05). Drug encapsulation using microparticles can prolong the effects of milrinone. We propose a new strategy for future drug delivery in patients with end-stage heart failure." @default.
• W2024930671 created "2016-06-24" @default.
• W2024930671 creator A5005758743 @default.
• W2024930671 creator A5011645957 @default.
• W2024930671 creator A5026041461 @default.
• W2024930671 creator A5036032663 @default.
• W2024930671 creator A5038623988 @default.
• W2024930671 creator A5071836777 @default.
• W2024930671 creator A5074860235 @default.
• W2024930671 date "2014-11-01" @default.
• W2024930671 modified "2023-09-29" @default.
• W2024930671 title "Sustained release of milrinone delivered via microparticles in a rodent model of myocardial infarction" @default.
• W2024930671 cites W1578030096 @default.
• W2024930671 cites W1694931843 @default.
• W2024930671 cites W1977718036 @default.
• W2024930671 cites W1978018856 @default.
• W2024930671 cites W1985407972 @default.
• W2024930671 cites W1985508815 @default.
• W2024930671 cites W1992226176 @default.
• W2024930671 cites W1993456710 @default.
• W2024930671 cites W1993748822 @default.
• W2024930671 cites W1996347612 @default.
• W2024930671 cites W2020398834 @default.
• W2024930671 cites W2022331655 @default.
• W2024930671 cites W2022981155 @default.
• W2024930671 cites W2050917537 @default.
• W2024930671 cites W2051219658 @default.
• W2024930671 cites W2061702892 @default.
• W2024930671 cites W2062873968 @default.
• W2024930671 cites W2071978292 @default.
• W2024930671 cites W2073528217 @default.
• W2024930671 cites W2079406923 @default.
• W2024930671 cites W2094672113 @default.
• W2024930671 cites W2102258973 @default.
• W2024930671 cites W2105852378 @default.
• W2024930671 cites W2123030659 @default.
• W2024930671 cites W2127038744 @default.
• W2024930671 cites W2156661377 @default.
• W2024930671 cites W2157551905 @default.
• W2024930671 cites W2164073426 @default.
• W2024930671 cites W2170386134 @default.
• W2024930671 cites W2319534362 @default.
• W2024930671 cites W1992211684 @default.
• W2024930671 doi "https://doi.org/10.1016/j.jtcvs.2014.07.033" @default.
• W2024930671 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25175952" @default.
• W2024930671 hasPublicationYear "2014" @default.
• W2024930671 type Work @default.
• W2024930671 sameAs 2024930671 @default.
• W2024930671 citedByCount "13" @default.
• W2024930671 countsByYear W20249306712015 @default.
• W2024930671 countsByYear W20249306712016 @default.
• W2024930671 countsByYear W20249306712017 @default.
• W2024930671 countsByYear W20249306712018 @default.
• W2024930671 countsByYear W20249306712021 @default.
• W2024930671 countsByYear W20249306712022 @default.
• W2024930671 countsByYear W20249306712023 @default.
• W2024930671 crossrefType "journal-article" @default.
• W2024930671 hasAuthorship W2024930671A5005758743 @default.
• W2024930671 hasAuthorship W2024930671A5011645957 @default.
• W2024930671 hasAuthorship W2024930671A5026041461 @default.
• W2024930671 hasAuthorship W2024930671A5036032663 @default.
• W2024930671 hasAuthorship W2024930671A5038623988 @default.
• W2024930671 hasAuthorship W2024930671A5071836777 @default.
• W2024930671 hasAuthorship W2024930671A5074860235 @default.
• W2024930671 hasBestOaLocation W20249306711 @default.
• W2024930671 hasConcept C112705442 @default.
• W2024930671 hasConcept C126322002 @default.
• W2024930671 hasConcept C162156334 @default.
• W2024930671 hasConcept C178853913 @default.
• W2024930671 hasConcept C179437574 @default.
• W2024930671 hasConcept C185592680 @default.
• W2024930671 hasConcept C202751555 @default.
• W2024930671 hasConcept C2776645727 @default.
• W2024930671 hasConcept C2778198053 @default.
• W2024930671 hasConcept C2780165375 @default.
• W2024930671 hasConcept C42219234 @default.
• W2024930671 hasConcept C43376680 @default.
• W2024930671 hasConcept C500558357 @default.
• W2024930671 hasConcept C55493867 @default.
• W2024930671 hasConcept C71924100 @default.
• W2024930671 hasConcept C78085059 @default.
• W2024930671 hasConcept C98274493 @default.
• W2024930671 hasConceptScore W2024930671C112705442 @default.
• W2024930671 hasConceptScore W2024930671C126322002 @default.
• W2024930671 hasConceptScore W2024930671C162156334 @default.
• W2024930671 hasConceptScore W2024930671C178853913 @default.
• W2024930671 hasConceptScore W2024930671C179437574 @default.
• W2024930671 hasConceptScore W2024930671C185592680 @default.
• W2024930671 hasConceptScore W2024930671C202751555 @default.
• W2024930671 hasConceptScore W2024930671C2776645727 @default.
• W2024930671 hasConceptScore W2024930671C2778198053 @default.
• W2024930671 hasConceptScore W2024930671C2780165375 @default.
• W2024930671 hasConceptScore W2024930671C42219234 @default.
• W2024930671 hasConceptScore W2024930671C43376680 @default.
• W2024930671 hasConceptScore W2024930671C500558357 @default.
• W2024930671 hasConceptScore W2024930671C55493867 @default.
• W2024930671 hasConceptScore W2024930671C71924100 @default.
• W2024930671 hasConceptScore W2024930671C78085059 @default.

• next